BRIEF published on 04/03/2026 at 07:05, 5 months 9 days ago Innate Pharma to Join Kempen Life Sciences Conference Biotechnology Investor Meetings Innate Pharma Cancer Immunotherapies Kempen Conference
BRIEF published on 04/03/2026 at 07:05, 5 months 9 days ago Innate Pharma participera à la Kempen Life Sciences Conference Conference Innate Pharma Biotechnologies Immunothérapies Kempen Life Sciences
BRIEF published on 04/03/2026 at 07:05, 5 months 9 days ago Innate Pharma will participate in the Kempen Life Sciences Conference Biotechnology Conference Innate Pharma Immunothérapies Kempen Life Sciences
BRIEF published on 04/03/2026 at 07:05, 5 months 9 days ago Innate Pharma participera à la conférence Kempen Life Sciences Biotechnologie Innate Pharma Réunions Avec Les Investisseurs Conférence De Kempen Immunothérapies Contre Le Cancer
PRESS RELEASE published on 04/03/2026 at 07:00, 5 months 9 days ago Informations privilégiées / Autres communiqués Innate Pharma participera à la conférence Kempen Life Sciences à Amsterdam, Pays-Bas, du 15 au 16 avril 2026, pour présenter ses traitements d'immunothérapies contre le cancer Conference Immunothérapie Cancer Innate Pharma Kempen Life Sciences
PRESS RELEASE published on 04/03/2026 at 07:00, 5 months 9 days ago Inside Information / Other news releases Innate Pharma to participate in the Kempen Life Sciences Conference on April 15-16, 2026, in Amsterdam, Netherlands. The company is developing immunotherapies for cancer patients Biotechnology Innate Pharma Immunothérapies Cancer Patients Kempen Life Sciences Conference
BRIEF published on 12/11/2025 at 07:05, 9 months 1 day ago Innate Pharma révèle son calendrier financier 2026 Biotechnologie Calendrier Financier Immunothérapie Innate Pharma Résultats 2026
BRIEF published on 12/11/2025 at 07:05, 9 months 1 day ago Innate Pharma Announces 2026 Financial Calendar Biotechnology Investor Information Innate Pharma Financial Schedule 2026 Key Dates
BRIEF published on 12/11/2025 at 07:05, 9 months 1 day ago Innate Pharma annonce son calendrier financier pour 2026 Biotechnologie Calendrier Financier Informations Pour Les Investisseurs Innate Pharma Dates Clés De 2026
BRIEF published on 12/11/2025 at 07:05, 9 months 1 day ago Innate Pharma reveals its 2026 financial calendar Biotechnology Financial Calendar Immunotherapy Innate Pharma 2026 Results
Published on 09/12/2026 at 02:35, 11 hours 37 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 12 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 7 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 47 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 12 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 42 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 57 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 2 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 28 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 57 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
